According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Separately, DZ Bank reissued a sell rating on shares of Sartorius in a report on Friday, July 19th.
Shares of OTCMKTS:SARTF opened at $164.10 on Thursday. The firm has a fifty day moving average price of $181.39 and a two-hundred day moving average price of $169.04. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.53 and a quick ratio of 0.85. Sartorius has a one year low of $109.50 and a one year high of $192.10. The company has a market cap of $5.61 billion, a price-to-earnings ratio of 54.34 and a beta of -0.06.
Sartorius (OTCMKTS:SARTF) last announced its quarterly earnings results on Friday, July 19th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.07. Sartorius had a net margin of 11.10% and a return on equity of 20.23%. The firm had revenue of $515.83 million during the quarter, compared to the consensus estimate of $482.51 million. Equities research analysts expect that Sartorius will post 3.53 EPS for the current fiscal year.
There is no company description available for Sartorius AG.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.